Tibet Duo Rui Pharmaceutical Co

Tibet Duo Rui Pharmaceutical Co Div.-Adj. PEG

Dividend-Adjusted PEG Ratio of Tibet Duo Rui Pharmaceutical Co (301075.SZ) as of Nov 17, 2026.

Div.-Adj. PEG

-

Last updated:

Dividend-Adjusted PEG Ratio of Tibet Duo Rui Pharmaceutical Co is 2026 - . Dividend-Adjusted PEG Ratio of Tibet Duo Rui Pharmaceutical Co was 2025 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tibet Duo Rui Pharmaceutical Co Stock analysis

What does Tibet Duo Rui Pharmaceutical Co do? Tibet Duo Rui Pharmaceutical Co., Ltd. generates revenue through the research, development, manufacture, and sale of chemical preparations and their raw materials. The company's core product, sodium acetate ringer injection, is used for supplementing body fluids, regulating electrolyte balance, and correcting acidosis. Additional products include compound electrolyte injection, compound mannitol injection, and cefotaxime sodium for injection, which are sold to healthcare providers and hospitals. The firm targets the pharmaceutical market segment focused on fluid and electrolyte management and antibiotic treatments. The company's revenue streams are derived from the sale of its proprietary chemical preparations, with sodium acetate ringer injection representing a key product line. Compound electrolyte injection and compound mannitol injection cater to specific medical needs, while cefotaxime sodium for injection serves as an antibiotic solution. These products are distributed to hospitals and healthcare facilities within China's pharmaceutical distribution network. Tibet Duo Rui Pharmaceutical's business model centers on developing and commercializing specialized injectable solutions for clinical use. The firm's product portfolio addresses critical healthcare requirements, including fluid replacement, electrolyte regulation, and infection treatment. Sales are directed toward medical institutions that require these specialized pharmaceutical products for patient care. Tibet Duo Rui Pharmaceutical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tibet Duo Rui Pharmaceutical Co stock

On Eulerpool you can find the complete historical development of Dividend-Adjusted PEG Ratio Tibet Duo Rui Pharmaceutical Co since 2006 – with annual values, charts, and detailed analysis.

The dividend-adjusted PEG ratio factors in dividend yield alongside earnings growth, providing a more complete valuation for income-paying stocks.

To evaluate Dividend-Adjusted PEG Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Dividend-Adjusted PEG Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Dividend-Adjusted PEG Ratio's Tibet Duo Rui Pharmaceutical Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Tibet Duo Rui Pharmaceutical Co

All Key Metrics — Tibet Duo Rui Pharmaceutical Co